Chronic Hepatitis C Infection Clinical Trial
Official title:
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)
This was a Phase 2/3, open-label, multicenter study to evaluate the pharmacokinetics (PK), efficacy, and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) with or without dasabuvir (DSV) and with or without ribavirin (RBV) in Hepatitis C virus (HCV) genotype 1 or 4 (GT1 or GT4)-infected pediatric participants of ≥ 3 to 17 years of age.
The study population for Part 1, the PK study, included GT1-infected participants who were noncirrhotic and treatment-naïve (TN). Part 2, the safety and efficacy study, included GT1 or GT4-infected participants who were TN or interferon ([IFN] or Pegylated-interferon alfa-2a or 2b [pegIFN] with or without RBV) treatment-experienced (TE) without cirrhosis or with compensated cirrhosis. In Part 1 and Part 2, the treatment regimen and duration were dependent on HCV GT, GT1 subtype, and cirrhosis status. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02216422 -
A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection
|
Phase 3 | |
| Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
| Completed |
NCT01700179 -
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
|
Phase 1 | |
| Completed |
NCT01704755 -
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
|
Phase 3 | |
| Completed |
NCT01225380 -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
|
Phase 2 | |
| Completed |
NCT01221298 -
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
|
Phase 2 | |
| Completed |
NCT01716585 -
A Study to Evaluate Chronic Hepatitis C Infection
|
Phase 3 | |
| Completed |
NCT02065999 -
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
|
||
| Completed |
NCT01715415 -
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
|
Phase 3 | |
| Completed |
NCT01453075 -
Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)
|
Phase 1 | |
| Completed |
NCT01011166 -
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
|
Phase 2 | |
| Completed |
NCT00557583 -
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT01586325 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients
|
Phase 1 | |
| Recruiting |
NCT02578693 -
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
|
||
| Recruiting |
NCT02583685 -
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
|
Phase 2 | |
| Completed |
NCT02576314 -
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
|
Phase 3 | |
| Not yet recruiting |
NCT01835938 -
Clinical Investigation of Erlotinib as an HCV Entry Inhibitor
|
Phase 1/Phase 2 | |
| Completed |
NCT01055821 -
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
|
Phase 2 | |
| Completed |
NCT01833533 -
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
|
Phase 3 | |
| Completed |
NCT01854697 -
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
|
Phase 3 |